280 related articles for article (PubMed ID: 26689406)
1. A Novel Folate-Targeted Nanoliposomal System of Doxorubicin for Cancer Targeting.
Lohade AA; Jain RR; Iyer K; Roy SK; Shimpi HH; Pawar Y; Rajan MG; Menon MD
AAPS PharmSciTech; 2016 Dec; 17(6):1298-1311. PubMed ID: 26689406
[TBL] [Abstract][Full Text] [Related]
2. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
[TBL] [Abstract][Full Text] [Related]
3. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
4. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
5. A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.
Huang Y; Yang T; Zhang W; Lu Y; Ye P; Yang G; Li B; Qi S; Liu Y; He X; Lee RJ; Xu C; Xiang G
Int J Nanomedicine; 2014; 9():4581-95. PubMed ID: 25302024
[TBL] [Abstract][Full Text] [Related]
6. Smart IR780 Theranostic Nanocarrier for Tumor-Specific Therapy: Hyperthermia-Mediated Bubble-Generating and Folate-Targeted Liposomes.
Guo F; Yu M; Wang J; Tan F; Li N
ACS Appl Mater Interfaces; 2015 Sep; 7(37):20556-67. PubMed ID: 26322900
[TBL] [Abstract][Full Text] [Related]
7. Effective tumor targeting and enhanced anti-tumor effect of liposomes engrafted with peptides specific for tumor lymphatics and vasculature.
Herringson TP; Altin JG
Int J Pharm; 2011 Jun; 411(1-2):206-14. PubMed ID: 21443937
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
9. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
10. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil.
Moghimipour E; Rezaei M; Ramezani Z; Kouchak M; Amini M; Angali KA; Dorkoosh FA; Handali S
Eur J Pharm Sci; 2018 Mar; 114():166-174. PubMed ID: 29247686
[TBL] [Abstract][Full Text] [Related]
11. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
[TBL] [Abstract][Full Text] [Related]
12. Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model.
de Oliveira Silva J; Fernandes RS; Ramos Oda CM; Ferreira TH; Machado Botelho AF; Martins Melo M; de Miranda MC; Assis Gomes D; Dantas Cassali G; Townsend DM; Rubello D; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2019 Oct; 118():109323. PubMed ID: 31400669
[TBL] [Abstract][Full Text] [Related]
13. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
Malhi SS; Budhiraja A; Arora S; Chaudhari KR; Nepali K; Kumar R; Sohi H; Murthy RS
Int J Pharm; 2012 Aug; 432(1-2):63-74. PubMed ID: 22531856
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer activity of doxorubicin-loaded liposomes co-modified with transferrin and folic acid.
Sriraman SK; Salzano G; Sarisozen C; Torchilin V
Eur J Pharm Biopharm; 2016 Aug; 105():40-9. PubMed ID: 27264717
[TBL] [Abstract][Full Text] [Related]
15. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
17. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
[TBL] [Abstract][Full Text] [Related]
18. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors.
Shmeeda H; Mak L; Tzemach D; Astrahan P; Tarshish M; Gabizon A
Mol Cancer Ther; 2006 Apr; 5(4):818-24. PubMed ID: 16648551
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
Battistini L; Burreddu P; Sartori A; Arosio D; Manzoni L; Paduano L; D'Errico G; Sala R; Reia L; Bonomini S; Rassu G; Zanardi F
Mol Pharm; 2014 Jul; 11(7):2280-93. PubMed ID: 24819754
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]